Stock Events

Tema Oncology 

$29.83
2
+$0.22+0.74% Today

Statistics

Day High
-
Day Low
-
52W High
29.99
52W Low
21.13
Volume
0
Avg. Volume
9,671
Mkt Cap
49.74M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Dec 23
$0.15
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CANC. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb is a major player in the oncology sector, developing similar cancer treatments and therapies.
Merck &
MRK
Mkt Cap318.55B
Merck is known for its strong portfolio in cancer drugs, directly competing in the oncology market.
Pfizer
PFE
Mkt Cap169.83B
Pfizer has a significant presence in oncology through its various cancer treatment solutions.
Novartis
NVS
Mkt Cap232.42B
Novartis offers a broad range of oncology products that compete in similar therapeutic areas as Tema Oncology.
Roche
RHHBY
Mkt Cap220.72B
Roche Holding AG is a leader in oncology, particularly in cancer immunotherapy, competing directly with Tema Oncology.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca has a strong focus on oncology, with numerous cancer drugs that compete with Tema Oncology's offerings.
AMGEN
AMGN
Mkt Cap177.72B
Amgen focuses on human therapeutics, including oncology, where it competes with Tema Oncology in cancer treatment.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences is involved in the development of oncology products, particularly in areas overlapping with Tema Oncology's focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals is engaged in the discovery of cancer treatments, competing in the oncology space.

About

Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Show more...
CEO
Country
US
ISIN
US87975E7013

Listings

XNAS
US
CANC